Author

L. Buluwela

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

S. Ali· 3 shared A. Bahreini· 2 shared A. V. Lee· 2 shared J. Gertz· 2 shared J. K. Richer· 2 shared J. M. Atkinson· 2 shared L. Zhu· 2 shared N. M. Priedigkeit· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. Ali

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

Z. Li, Y. Wu, M. E. Yates, N. Tasdemir, A. Bahreini, J. Chen, K. M. Levine, N. M. Priedigkeit, S. Ali, L. Buluwela, S. Arnesen, J. Gertz, J. K. Richer, B. Troness, D. El-Ashry, , S. Oesterreich

This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.

bioRxiv · Feb 10, 2021 · PreprintCancer Biology

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Z. Li, Y. Wu, A. Bahreini, N. M. Priedigkeit, K. Ding, C. A. Sartorius, L. Miller, M. Rosenzweig, N. Wagle, J. K. Richer, W. J. Muller, L. Buluwela, S. Ali, Y. Fang, L. Zhu, , S. Oesterreich

This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.

bioRxiv · Dec 29, 2020 · PreprintCancer Biology

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer

C. Gemma, C. Lai, A. Singh, A. Belfiore, N. Portman, H. Z. Milioli, M. Periyasamy, S. Abuelmaaty, A. J. Nicholls, C. Davies, N. R. Patel, G. Simmons, H. Fan, V. Nguyen, L. Magnani, , S. Ali

This study identifies VGLL1 as a driver of resistance to endocrine therapy in ER+ breast cancer and shows that targeting VGLL1/TEAD interaction can inhibit resistant cell growth.

bioRxiv · Nov 29, 2020Cancer Biology